JGC
IMCR icon

J. Goldman & Co’s Immunocore IMCR Stock Holding History

J. Goldman & Co’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,500
Closed -$922K – 454
2023
Q4 		$922K Buy
+13,500
New +$702K 0.04% 234

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

J. Goldman & Co's IMCR Position: Q2 2026 in Review

J. Goldman & Co reduced its Immunocore (IMCR) stake by 53% in Q2 2026, selling an estimated $1.81M and leaving 53,430 shares worth $1.7M. The position accounts for 0.04% of the portfolio, ranked #373.

J. Goldman & Co first reported a position in IMCR in Q2 2021 and has held it in 3 quarters since. The position peaked at $3.46M in Q1 2026. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • J. Goldman & Co held 53,430 shares of Immunocore worth $1.7M as of Q2 2026.
  • J. Goldman & Co sold 61,319 Immunocore shares in Q2 2026, an estimated $1.81M.
  • Immunocore made up 0.04% of J. Goldman & Co's portfolio in Q2 2026, its #373 holding.
  • J. Goldman & Co first reported a position in Immunocore in Q2 2021 and has held it in 3 quarters since.
  • J. Goldman & Co's Immunocore position peaked at $3.46M in Q1 2026.
  • 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.